Alpha Teknova, Inc. launched the Company's first proprietary product line, AAV-Tek Solutions, specifically created to address critical pain points in the AAV gene therapy development workflow. The first product released in this line - the AAV-Tek AEX Buffer Screening Kit - is available for purchase and can save gene therapy developers months of process development time. The AAV-Tek A EX Buffer Screening Kit, developed by Teknova's Research and Development team, is a proprietary, off-the-shelf selection of discrete buffers that significantly reduces the time it takes to find the ideal buffer formulation to optimize the separation of empty and full capsids during the anion exchange (AEX) purification step.

After conducting a robust design of experiments with hundreds of AEX runs, including extensive validation against four critical quality attributes (infectivity, recovery, purity, and peak separation), Teknova identified and verified a set of seven equilibration and elution buffers optimized for use across a variety of upstream workflows, transgenes, and downstream purification platforms. By removing the need for repeated and extensive buffer formulation exploration, the AAV-TekAEX Buffer Screening Kit can save gene therapy developers working with AAV2 months in their development timelines, enabling them to discover novel breakthroughs faster. Developers are able to seamlessly scale from process development to clinical production by leveraging Teknova's modular manufacturing platform, hands-on scientific and technical support teams, and more than 25 years of experience in reagents bioprocessing production. The AAV-Tik AEX Buffer Screening Kit for AAV2 is available for purchase via phone, email, or online, and is priced at $1,200.

Additionally, Teknova will release a kit for AAV8 in the coming months and kits to address additional serotypes later this year.